Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations

Dow Jones01-09

By Elias Schisgall

Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026.

Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year.

Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million.

Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

January 08, 2026 11:24 ET (16:24 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2602396401?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 00:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2602396401","market":"sh","top_or_hot":-1,"title":"Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n</p>\n<p>\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n</p>\n<p>\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n</p>\n<p>\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 11:24 ET (16:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmarin Shares Rise on Hitting Positive Cash Flow Ahead of Expectations\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-09 00:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n</p>\n<p>\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n</p>\n<p>\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n</p>\n<p>\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 08, 2026 11:24 ET (16:24 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2602396401","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2602396401","pubTimestamp":1767889440,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026.Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year.Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million.Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AMRN":"阿玛琳"},"translate_title":"Amarin股价因现金流超出预期而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRN":0.9},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Amarin rose after the pharmaceutical company said it achieved positive cash flow in the fourth quarter of 2025, ahead of its prior expectation of hitting the benchmark in 2026. \n\n\n  Shares rose 10% to $15.48 late Thursday morning. The stock has gained 40% in the past year. \n\n\n  Amarin said Thursday that it expects to report net revenue for the fourth quarter of between $48 million and $53 million, and revenue for the full year between $212 million and $217 million. \n\n\n  Amarin said it had realized roughly 50% of the estimated $70 million in operational savings from its 2025 restructuring, with full savings expected by June. The restructuring is estimated to incur a charge of $37 million to $40 million, up from a prior range of $30 million to $37 million. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 11:24 ET (16:24 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2602396401","isCrawlerRequest":true}